150 related articles for article (PubMed ID: 25162219)
1. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Ikeda H; Ueda Y; Yamaguchi T; Nasu H; Ohtani H; Shigematsu H; Kagawa Y; Inoue Y
Ther Drug Monit; 2015 Apr; 37(2):229-35. PubMed ID: 25162219
[TBL] [Abstract][Full Text] [Related]
2. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
Liao K; Liu Y; Ai CZ; Yu X; Li W
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
[TBL] [Abstract][Full Text] [Related]
3. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
4. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Ortega-Vázquez A; Dorado P; Fricke-Galindo I; Jung-Cook H; Monroy-Jaramillo N; Martínez-Juárez IE; Familiar-López I; Peñas-Lledó E; LLerena A; López-López M
Pharmacogenomics J; 2016 Jun; 16(3):286-92. PubMed ID: 26122019
[TBL] [Abstract][Full Text] [Related]
5. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
6. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
[TBL] [Abstract][Full Text] [Related]
7. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
8. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
Hung CC; Huang HC; Gao YH; Chang WL; Ho JL; Chiou MH; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Sep; 13(12):1339-49. PubMed ID: 22966884
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V; Perucca E
Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
[TBL] [Abstract][Full Text] [Related]
11. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Lee SY; Lee ST; Kim JW
J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
[TBL] [Abstract][Full Text] [Related]
12. The effect of polymorphic metabolism enzymes on serum phenytoin level.
Ozkaynakci A; Gulcebi MI; Ergeç D; Ulucan K; Uzan M; Ozkara C; Guney I; Onat FY
Neurol Sci; 2015 Mar; 36(3):397-401. PubMed ID: 25311916
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of effects of
Kanjanasilp J; Sawangjit R; Phanthaisong S; Borihanthanawuth W
Pharmacogenomics; 2021 Jul; 22(10):629-640. PubMed ID: 34060344
[No Abstract] [Full Text] [Related]
14. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.
Yampayon K; Sukasem C; Limwongse C; Chinvarun Y; Tempark T; Rerkpattanapipat T; Kijsanayotin P
Eur J Clin Pharmacol; 2017 Jul; 73(7):855-865. PubMed ID: 28391407
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258
[TBL] [Abstract][Full Text] [Related]
16. Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
Fohner AE; Rettie AE; Thai KK; Ranatunga DK; Lawson BL; Liu VX; Schaefer CA
Clin Transl Sci; 2020 Sep; 13(5):1004-1009. PubMed ID: 32216088
[TBL] [Abstract][Full Text] [Related]
17. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
[TBL] [Abstract][Full Text] [Related]
18. Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients.
Tobler A; Mühlebach S
Int J Clin Pharm; 2013 Oct; 35(5):790-7. PubMed ID: 23812678
[TBL] [Abstract][Full Text] [Related]
19. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M
Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
[TBL] [Abstract][Full Text] [Related]
20. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]